Recombinant Human IGFBP3 Protein，His

Insulin-like growth factor binding protein 3 (IGFBP3) is a critical regulator of the insulin-like growth factor (IGF) signaling pathway, which plays a vital role in cellular growth, development, and apoptosis. As the most abundant IGFBP in circulation, IGFBP3 not only modulates IGF activity but also has IGF-independent effects, influencing cell adhesion, matrix interaction, and apoptosis in various tissues. Dysregulation of IGFBP3 has been associated with numerous diseases, including cancer, diabetes, and cardiovascular disorders, making it a significant focus of research. The recombinant production of IGFBP3 in various expression systems, including bacterial, yeast, and mammalian cells, has facilitated a more profound understanding of its biological functions and therapeutic potential. Recent studies have explored IGFBP3's roles in tumor biology, revealing that it can act as a tumor suppressor in certain contexts while promoting proliferation and invasion in others, depending on the cellular environment and the presence of IGFs. Additionally, IGFBP3 is being investigated as a potential biomarker for disease diagnosis and prognosis, particularly in oncology. The development of recombinant IGFBP3 not only aids in elucidating its physiological roles but also paves the way for potential clinical applications, including targeted therapies and novel treatment strategies for diseases linked to IGF signaling dysregulation. Understanding the structure-function relationship of IGFBP3 through recombinant technologies is crucial for harnessing its therapeutic potential and addressing various pathologies associated with altered IGF signaling.